| Title : Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner - Kitada_2017_BMJ.Open.Diabetes.Res.Care_5_e000391 |
| Author(s) : Kitada M , Tsuda SI , Konishi K , Takeda-Watanabe A , Fujii M , Kanasaki K , Nishizawa M , Nakagawa A , Koya D |
| Ref : BMJ Open Diabetes Res Care , 5 :e000391 , 2017 |
| Abstract : Kitada_2017_BMJ.Open.Diabetes.Res.Care_5_e000391 |
| ESTHER : Kitada_2017_BMJ.Open.Diabetes.Res.Care_5_e000391 |
| PubMedSearch : Kitada_2017_BMJ.Open.Diabetes.Res.Care_5_e000391 |
| PubMedID: 28761658 |
Kitada M, Tsuda SI, Konishi K, Takeda-Watanabe A, Fujii M, Kanasaki K, Nishizawa M, Nakagawa A, Koya D (2017)
Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
BMJ Open Diabetes Res Care
5 :e000391
Kitada M, Tsuda SI, Konishi K, Takeda-Watanabe A, Fujii M, Kanasaki K, Nishizawa M, Nakagawa A, Koya D (2017)
BMJ Open Diabetes Res Care
5 :e000391